Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Long Cast Advisers Avram Fisher | “CCRN ($8.24 avg price). We are revisiting the nurse staffing company we first owned back in 2019 and sold when COVID comps turned negative. At $8 / share and with 32M shares out, the company has a $260M market capitalization. At its most recent quarter, the company had $99M in net cash and no debt. In December it received a $20M termination payment following its failed $615M acquisition by AYA. This leaves it with over 40% of its market cap in cash and a pro forma enterprise value of $140M. Of the large nurse staffing companies, CCRN is one of the smallest and has long lagged its peer group in profitability. We originally owned this because founder Kevin Clark had returned after a +20-year absence, and the stock was cheap. We had anticipated that his management and entrepreneurial experience would alter the culture and cadence of the business, and help it achieve margins closer to industry averages. The COVID boom certainly changed the cadence of the business, enabling the company to pay down debt, make sound acquisitions, buy back stock and accumulate cash. It also saw a change in management: In 2021, Clark hired John Martins from privately held AYA Healthcare to run the nurse staffing division. Martins was promoted to CEO in 2022 and Clark remained Chairman. In late 2024, AYA agreed to purchase CCRN for $615M, but the merger collapsed in late 2025 after FTC delays and the unexpected death of AYA's founder. After the merger's demise, Martins departed and Clark returned as CEO. Thus, the investment case is a bit similar to 2019, but today it is cheaper, with a stronger balance sheet and a stronger presence in higher margin niches including locum tenens, home health care and education staffing. Nurse staffing remains highly competitive and pricing has not returned to pre-COVID levels, but I think CCRN is nearing positive comps and we are investing ahead of this turn, with a margin of safety offered by a low multiple, optionality offered by excess cash, and the possibility that Clark's third go-round can sustainably improve margins. BSD Analysis: Cross Country is a staffing company living through the unwind of pandemic-era excess. Travel nurse pricing collapsed, but healthcare labor shortages did not disappear. Investors extrapolate peak-margin conditions in reverse and assume permanent impairment. The normalized business is smaller, but still structurally relevant. Cost discipline and capital returns matter more than growth now. Optionality exists if labor tightness resurfaces faster than expected. This is healthcare labor cyclicality, not obsolescence.” | BULL | Q4 2025 Jan 1, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
